1-2 of 2
Sara A. Holstein, MDPhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma

Dan T. Vogl, MD, Jonathan L. Kaufman, MD, Sara A. Holstein, MDPhD, Omar Nadeem, MD, Elizabeth O'Donnell, MD, Kaveri Suryanarayan, MD, Sabrina Collins, Xavier Parot, MD, Maria Chaudhry, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-141219
Published: 2020
Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Jonathan L. Kaufman, MD, Jacob P. Laubach, Douglas Sborov, MD MS, Brandi Reeves, MD, Cesar Rodriguez, MD, Ajai Chari, Rebecca W. Silbermann, MD, Luciano J. Costa, MD PhD, Larry D. Anderson, Jr., MD PhD, Nitya Nathwani, MD, Nina Shah, MD, Yvonne A. Efebera, MD MPH, Sara A. Holstein, MDPhD, Caitlin Costello, Andrzej Jakubowiak, MD PhD, Tanya M. Wildes, MD MSCI, Robert Z. Orlowski, MDPhD, Kenneth H. Shain, MD PhD, Andrew J. Cowan, Yana Lutska, PharmD, Padma Bobba, Huiling Pei, PhD, Jon Ukropec, PhD, Jessica Vermeulen, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD, Peter M. Voorhees
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-137109
Published: 2020